|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||0.1530 - 0.1694|
|52 Week Range||0.1530 - 1.3250|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022 - Nov 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.83|
Subscribe to Yahoo Finance Plus to view Fair Value for TRVN
CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York. Presentation DetailsDate: Monday, September 12, 2022Time: 4:30pm ETWeb
Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...